HQH (HQH) Stock Price & Analysis
HQH (HQH) rose 1.65% to USD 21.5 as of July 25, 2026 at 02:24 UTC, according to Nexqual real-time market data.
HQH last closed at USD 21.15; the session ranged USD 21.16–21.73 on volume of 642,526 shares. Market capitalization is —, with a 52-week range of USD 15.51–22.29 (NYQ). Source: Nexqual, July 25, 2026 at 02:24 UTC.
Key Statistics (as of July 25, 2026 at 02:24 UTC)
| Price | USD 21.5 |
|---|---|
| Change | ▲ 1.65% (up) |
| Previous Close | USD 21.15 |
| Open | USD 21.39 |
| Day Range | USD 21.16 – 21.73 |
| 52-Week Range | USD 15.51 – 22.29 |
| Volume | 642,526 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (HQH)
Nexqual's technical model rates HQH "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 02:24 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.08 (neutral) |
| vs SMA50 | Above (USD 20.4) |
| MACD | 0.19 (positive) |
Analyst Ratings (HQH)
Wall Street analysts rate HQH "None", per Nexqual as of July 25, 2026 at 02:24 UTC.
| Consensus Rating | None |
|---|
Earnings (HQH)
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Financials & Fundamentals (HQH)
| Total Revenue | $5.54M |
|---|---|
| Revenue Growth (YoY) | -42.10% |
| Gross Margin | +100.00% |
| Operating Margin | -125.50% |
| Profit Margin | +4561.32% |
| ROE | +24.21% |
| Current Ratio | 1.03 |
| Total Debt | $0 |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Financial Health Score (HQH)
Nexqual rates HQH's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 02:24 UTC.
| Growth | Critical — Revenue -42% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Strong — ROE 24%, ROA -0.3% |
Ownership (HQH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +22.94% |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Leadership (HQH)
HQH is led by Jason C. Akus, Vice President of Research and Portfolio Manager, per Nexqual as of July 25, 2026 at 02:24 UTC.
| Vice President of Research and Portfolio Manager | Jason C. Akus |
|---|---|
| Senior Vice President of Research and Portfolio Manager | Christopher F. Brinzey |
| Senior Vice President of Research and Portfolio Manager | Frank T. Gentile (age 63) |
Major Backers & Investors (HQH)
Notable institutional backers of HQH include Morgan Stanley, Raymond James Financial, Inc., Penserra Capital Management LLC, according to Nexqual as of July 25, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 7.91% |
| Raymond James Financial, Inc. | 2.09% |
| Penserra Capital Management LLC | 2.01% |
| Amplify ETF Trust-Amplify CEF High Income ETF | 2% |
| Advisors Asset Management, Inc. | 1.01% |
| LPL Financial LLC | 0.97% |
| Royal Bank of Canada | 0.91% |
| Ameriprise Financial, Inc. | 0.82% |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HQL | TeklaLife Sciences Investors | USD 19.25 | ▼ 2.38% |
| THW | Tekla World Healthcare Fund Sha | USD 13.12 | ▼ 0.98% |
| THQ | Tekla Healthcare Opportunies Fu | USD 18.55 | ▼ 1.28% |
| RVT | Royce Value Trust, Inc. | USD 18.04 | ▼ 0.06% |
| UTF | Cohen & Steers Infrastructure F | USD 28.07 | ▲ 1.15% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:24 UTC. This page is informational and not investment advice.